Drug intelligence / Profile preview

AqT-Exatecan

Development stage: Preclinical
Lead developer: AqueaTether Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

AqT-Exatecan is a topoisomerase I inhibitor payload developed by AqueaTether Therapeutics, a subsidiary or partner of CellMosaic. It consists of the camptothecin derivative exatecan conjugated to the proprietary AqueaTether (AqT) platform. The AqT technology utilizes a highly hydrophilic, monodisperse, and biodegradable polymer tether designed to improve the solubility and conjugation efficiency of hydrophobic payloads like exatecan. As a topoisomerase I inhibitor, the molecule stabilizes the DNA-topoisomerase I cleavable complex, preventing DNA religation and inducing lethal double-strand breaks during DNA replication. AqT-Exatecan is marketed as a platform asset or reagent for biopharmaceutical companies to develop next-generation antibody-drug conjugates (ADCs) with optimized pharmacokinetic and safety profiles.

Other names: Exatecan AqueaTether

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on AqT-Exatecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AqT-Exatecan.

Explore the full profile